Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells:: APC8015 (Provenge®)

被引：39
|
作者：
Harzstark, Andrea L. [1 ]
Small, Eric J. [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
dendritic cell; immunotherapy; prostate cancer; prostatic acid phosphatase; Provenge;
D O I：
10.1517/14712598.7.8.1275
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Dendritic cells are deficient both in number and function in patients with cancer. Loaded dendritic cell therapies aim to overcome this deficiency by delivering antigens to antigen-presenting cells under ex vivo conditions, improving dendritic cell function. APC8015 (Provenge((R)); Dendreon Corp., Seattle, WA) is a novel immunotherapeutic, which consists of autologous dendritic cells pulsed ex vivo with PA2024, a recombinant fusion protein consisting of granulocyte macrophage colony-stimulating factor and prostatic acid phosphatase, as an immunogenic agent. A Phase III randomized clinical trial has demonstrated a survival benefit in patients with metastatic hormone-refractory prostate cancer. This review summarizes the clinical trials using APC801 5 in prostate cancer and discusses its future role in the treatment of prostate cancer.
引用
下载
收藏
页码：1275 / 1280
页数：6
相关论文
共 50 条
  • [1] Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
    Small, EJ
    Fratesi, P
    Reese, DM
    Strang, G
    Laus, R
    Peshwa, MV
    Valone, FH
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) : 3894 - 3903
  • [2] Immunotherapy (APC8015) for androgen dependent, biochemically-relapsed prostate cancer.
    Rini, BI
    Beinart, G
    Small, EJ
    Verjee, S
    Hershberg, RM
    JOURNAL OF UROLOGY, 2005, 173 (04): : 276 - 276
  • [3] Targeting antigen-loaded liposomes to myeloid antigen presenting cells
    Capini, C
    Jaturanpinyo, M
    Gautam, A
    Davies, N
    Thomas, R
    TISSUE ANTIGENS, 2005, 66 (05): : 372 - 373
  • [4] Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
    Lin, Amy M.
    Hershberg, Robert M.
    Small, Eric J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (05) : 434 - 441
  • [5] Turning tumor cells into antigen-presenting cells for cancer immunotherapy
    Lopez-Lago, Miguel
    Williams, William
    Wiseman, Charles
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer:: A phase 2 trial
    Burch, PA
    Croghan, GA
    Gastineau, DA
    Jones, LA
    Kaur, JS
    Kylstra, JW
    Richardson, RL
    Valone, FH
    Vuk-Pavlovic, S
    PROSTATE, 2004, 60 (03): : 197 - 204
  • [7] Targeting and Specific Activation of Antigen-Presenting Cells by Endogenous Antigen-Loaded Nanoparticles Elicits Tumor-Specific Immunity
    Chang, Hao-Cai
    Zou, Zheng-Zhi
    Wang, Qiu-Hong
    Li, Jie
    Jin, Huan
    Yin, Qian-Xia
    Xing, Da
    ADVANCED SCIENCE, 2020, 7 (01)
  • [8] Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer
    Wilke, Cailin Moira
    Kryczek, Ilona
    Zou, Weiping
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2011, 30 (2-3) : 120 - 126
  • [9] Evaluation of gammadelta T cells as antigen-presenting cells for cancer immunotherapy
    Yamasaki, A.
    Onishi, H.
    Morisaki, T.
    Tanaka, M.
    Katano, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Engineering antigen-presenting cells for immunotherapy of autoimmunity
    Smith, Clinton T.
    Wang, Zhenyu
    Lewis, Jamal S.
    ADVANCED DRUG DELIVERY REVIEWS, 2024, 210
12345